Rethinking Fever as Indicator for Blood Culture in Community-Acquired Pneumonia
In patients with community-acquired pneumonia, using fever as an indicator of blood culture necessity for detecting bacteremia warrants reevaluation.
Pneumonia
20-Valent Pneumococcal Conjugate Vaccine Safe, Effective in Phase 3 Trial
Pfizer announced topline data from one of its phase 3 studies for 20vPnC for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults.
Antibiotics May Not Affect Outcomes in Children With Suspected Pneumonia
Outcomes do not differ in children with suspected CAP discharged from the emergency department with or without antibiotic prescriptions.
Neuraminidase Inhibitor Treatment for Influenza B-Related Pneumonia
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
Pneumonia Mortality Not Improved With Empiric Anti-MRSA Therapy
Anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy in addition to standard pneumonia therapy does not improve mortality.
Poll Results: Anti-Influenza Therapy in Community-Acquired Pneumonia
Review the results of a recent reader poll on using anti-influenza therapies in patients with community-acquired pneumonia.
ACIP: 2020 Adult Immunization Schedule Updates
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the adult immunization schedule for ages 19 years and older in the United States.
Three-Drug Combination Receives FDA Priority Review for HAP, VAP
The FDA has accepted for review a supplemental New Drug Application for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Invasive Pneumococcal Disease Risk Increased in Children With Asthma
Pediatric patients with asthma who receive pneumococcal conjugate vaccine as part of their regular immunization schedule still have a higher risk for invasive pneumococcal disease.
FDA: Bacitracin for Injection to Be Withdrawn From Market
The FDA has requested that all manufacturers of bacitracin for injection voluntarily withdraw their product from the market.
Next post in Pneumonia
